## Highlights of This Issue

### SPECIAL FEATURES

- **Finding the Right Dose for Cancer Therapeutics—Can We Do Better?**
  Eric H. Rubin and Keaven M. Anderson
  See article p. 1289

- **Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer**
  Amina Zoubeidi, Kim Chi, and Martin Gleave

- **Targeting the RB-pathway in Cancer Therapy**
  Erik S. Knudsen and Jean Y.J. Wang

- **A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations**
  Eleni Efstatiou and Christopher J. Logothetis

## HUMAN CANCER BIOLOGY

- **High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma**

- **Frequent Downregulation of miR-34 Family in Human Ovarian Cancers**
  David C. Corney, Chang-II Hwang, Andres Matoso, Markus Vogt, Andrea Flesken-Nikitin, Andrew K. Godwin, Aparna A. Kamat, Eleni Efstatiou, Heiko Hermeking, and Alexander Yu. Nikitin

## CANCER THERAPY: PRECLINICAL

- **Comprehensive MicroRNA Profiling for Head and Neck Squamous Cell Carcinomas**
  Angela B.Y. Hui, Michelle Lenarduzzi, Tiffany Krushel, Levi Waldron, Melania Pintilie, Wei Shi, Bayardo Perez-Ordonez, Igor Jurisica, Brian O'Sullivan, John Waldron, Pat Gullane, Bernard Cummings, and Fei-Fei Liu

- **X-Linked Ectodermal Dysplasia Receptor Is Downregulated in Breast Cancer via Promoter Methylation**
  Vasu Punj, Hittu Matta, and Preet M. Chaudhary

- **Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias**

- **AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer**

- **Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models**
  Kazushi Watanabe, Susumu Tanimura, Aya Uchiyama, Toshikazu Sakamoto, Takumi Kawabata, Kei-ichi Ozaki, and Michiaki Kohno
Leona Downey, Robert B. Livingston, Maria Koehler, Michael Arbushites, Lisa Williams, Angela Santiago, Roberta Guzman, Ivonne Villalobos, Angelo Di Leo, and Michael F. Press

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
Rajul K. Jain, J. Jack Lee, David Hong, Maurie Markman, Jing Gong, Aung Naing, Jennifer Wheler, and Razelle Kurzrock See commentary p. 1085

Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer
Charles A. Kunos, Steven Waggoner, Vivian von Gruenigen, Elisa Eldermire, John Pink, Afshin Dowlati, and Timothy J. Kinsella

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
Dae Ho Lee, Keunchil Park, Jooh Hang Kim, Jong-Seok Lee, Sang Won Shin, Jin-Hyoung Kang, Myung-Ju Ahn, Jin Seok Ahn, Cheolwon Suh, and Sang-We Kim

Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)

Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer
Shuhang Wang, Tongtong An, Jie Wang, Jun Zhao, Zhijie Wang, Mingliu Zhuo, Hua Bai, Lu Yang, Yan Zhang, Xin Wang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, and Meina Wu

Smoking and Colorectal Cancer in Lynch Syndrome: Results from the Colon Cancer Family Registry and The University of Texas M.D. Anderson Cancer Center
Mala Pande, Patrick M. Lynch, John L. Hopper, Mark A. Jenkins, Steve Gallinger, Robert W. Haile, Loic LeMarchand, Noralane M. Lindor, Peter T. Campbell, Polly A. Newcomb, John D. Potter, John A. Baron, Marsha L. Frazier, and Christopher I. Amos

Studies of TMPRSS2-ERG Gene Fusions in Diagnostic Trans-Rectal Prostate Biopsies
Gerhardt Attard, Johann S. de Bono, Jeremy Clark, and Colin S. Cooper

Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?
Peter A. Kavsak, Hal Hirte, and Sebastien J. Hotte

Correction: A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors
1343

Correction: The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y] Ibritumomab Tuxetan for Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preclinical Findings and Results of a Phase I Trial

Studies of TMPRSS2-ERG Gene Fusions in Diagnostic Trans-Rectal Prostate Biopsies
Gerhardt Attard, Johann S. de Bono, Jeremy Clark, and Colin S. Cooper

Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?
Peter A. Kavsak, Hal Hirte, and Sebastien J. Hotte

Correction: A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors
1343

Correction: The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y] Ibritumomab Tuxetan for Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preclinical Findings and Results of a Phase I Trial

The Journal of Clinical and Translational Research v www.aacrjournals.org
ABOUT THE COVER

Expression of the miR-34 family was found to be frequently reduced in human epithelial ovarian cancer, particularly so in tumors with p53 mutations. The figure shows miR-34a expression (dark blue) in ovarian serous adenocarcinoma as determined by in situ hybridization with locked nucleic acid–modified probes. Immunohistochemistry in serial sections revealed significant inverse correlation between miR-34a and its target MET, an oncogene commonly overexpressed in advanced stages of cancer. For details, see the article by Corney and colleagues on page 1119 of this issue.